Literature DB >> 18223665

Effect of CCR5 receptor antagonists on endocytosis of the human CCR5 receptor in CHO-K1 cells.

J Longden1, E-L Cooke, S J Hill.   

Abstract

BACKGROUND AND
PURPOSE: The CCR5 chemokine receptor is a member of the G protein-coupled receptor (GPCR) family that is expressed by macrophages, memory T-lymphocytes and dendritic cells and is activated by chemotactic proteins (e.g. MIP-1alpha [CCL3], MIP-1beta [CCL4] and RANTES [CCL5]). CCR5 is also the principal co-receptor for macrophage-tropic strains of human immunodeficiency virus-1 (HIV-1) and some chemokines can inhibit HIV-1 infection by stimulating CCR5 receptor endocytosis. The aim of this study was to evaluate the effect of CCR5 antagonists on CCR5 endocytosis. EXPERIMENTAL APPROACH: The effects of CCR5 agonists and antagonists on receptor internalization in CHO cells, expressing a C-terminal green fluorescent protein-tagged human CCR5 receptor (CCR5-GFP), were quantified using a confocal imaging plate reader. KEY
RESULTS: MIP-1alpha [CCL3], MIP-1beta [CCL4] and RANTES [CCL5] were all able to stimulate potently the internalization of CCR5-GFP. This effect was inhibited by the non-peptide antagonist TAK 779. The CCR5 peptide antagonist met-RANTES antagonized MIP-1alpha-mediated increases in intracellular free calcium but was also able to stimulate a substantial internalization of the human CCR5-GFP receptor. However, CHO cells exhibited an aminopeptidase activity that was able to metabolize sufficient met-RANTES into an agonist metabolite capable of stimulating calcium mobilization via CCR5 receptors in naïve cells. CONCLUSIONS AND IMPLICATIONS: These data suggest that there is an endogenous aminopeptidase activity on the surface of CHO cells, that produces a slow internalization of the receptor following a time-dependent conversion of receptor-bound met-RANTES from a CCR5 receptor antagonist into a CCR5 agonist molecule.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18223665      PMCID: PMC2437898          DOI: 10.1038/sj.bjp.0707691

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

Review 1.  Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors.

Authors:  Wieslaw Kazmierski; Neil Bifulco; Hanbiao Yang; Larry Boone; Felix DeAnda; Chris Watson; Terry Kenakin
Journal:  Bioorg Med Chem       Date:  2003-07-03       Impact factor: 3.641

Review 2.  The ins and outs of G protein-coupled receptor trafficking.

Authors:  Adriano Marchese; Catherine Chen; You-Me Kim; Jeffrey L Benovic
Journal:  Trends Biochem Sci       Date:  2003-07       Impact factor: 13.807

3.  Receptor activity-independent recruitment of betaarrestin2 reveals specific signalling modes.

Authors:  Sonia Terrillon; Michel Bouvier
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

Review 4.  Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells.

Authors:  Antal Rot; Ulrich H von Andrian
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

Review 5.  AT4 receptor is insulin-regulated membrane aminopeptidase: potential mechanisms of memory enhancement.

Authors:  Anthony L Albiston; Tomris Mustafa; Sharon G McDowall; Frederick A O Mendelsohn; Joohyung Lee; Siew Yeen Chai
Journal:  Trends Endocrinol Metab       Date:  2003-03       Impact factor: 12.015

6.  Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP).

Authors:  Rebecca A Lew; Tomris Mustafa; Siying Ye; Sharon G McDowall; Siew Yeen Chai; Anthony L Albiston
Journal:  J Neurochem       Date:  2003-07       Impact factor: 5.372

7.  Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2.

Authors:  Huijun Wei; Seungkirl Ahn; Sudha K Shenoy; Sadashiva S Karnik; László Hunyady; Louis M Luttrell; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-29       Impact factor: 11.205

8.  Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors.

Authors:  Mounia Azzi; Pascale G Charest; Stéphane Angers; Guy Rousseau; Trudy Kohout; Michel Bouvier; Graciela Piñeyro
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-17       Impact factor: 11.205

9.  Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different pathways.

Authors:  Antonio Rapacciuolo; Shayela Suvarna; Liza Barki-Harrington; Louis M Luttrell; Mei Cong; Robert J Lefkowitz; Howard A Rockman
Journal:  J Biol Chem       Date:  2003-06-23       Impact factor: 5.157

10.  Endogenous cystinyl aminopeptidase in Chinese hamster ovary cells: characterization by [125I]Ang IV binding and catalytic activity.

Authors:  Heidi Demaegdt; Patrick Vanderheyden; Jean-Paul De Backer; Sabrina Mosselmans; Hilde Laeremans; Minh Tam Le; Veerle Kersemans; Yvette Michotte; Georges Vauquelin
Journal:  Biochem Pharmacol       Date:  2004-09-01       Impact factor: 5.858

View more
  8 in total

1.  Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development.

Authors:  Rafael E Marques; Rodrigo Guabiraba; Juliana L Del Sarto; Rebeca F Rocha; Ana Luiza Queiroz; Daniel Cisalpino; Pedro E Marques; Carolina C Pacca; Caio T Fagundes; Gustavo B Menezes; Maurício L Nogueira; Danielle G Souza; Mauro M Teixeira
Journal:  Immunology       Date:  2015-06-01       Impact factor: 7.397

2.  CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network.

Authors:  Jean-Michel Escola; Gabriel Kuenzi; Hubert Gaertner; Michelangelo Foti; Oliver Hartley
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

3.  CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5.

Authors:  Kien Pham; Defang Luo; Che Liu; Jeffrey K Harrison
Journal:  J Neuroimmunol       Date:  2012-03-16       Impact factor: 3.478

4.  Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.

Authors:  Hirotomo Nakata; Michael Kruhlak; Wakako Kamata; Hiromi Ogata-Aoki; Jianfeng Li; Kenji Maeda; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antivir Ther       Date:  2010

5.  Structural and functional studies of the potent anti-HIV chemokine variant P2-RANTES.

Authors:  Hongjun Jin; Ioannis Kagiampakis; Pingwei Li; Patricia J Liwang
Journal:  Proteins       Date:  2010-02-01

6.  CCL3-CCR5 axis contributes to progression of esophageal squamous cell carcinoma by promoting cell migration and invasion via Akt and ERK pathways.

Authors:  Takayuki Kodama; Yu-Ichiro Koma; Noriaki Arai; Aya Kido; Naoki Urakawa; Mari Nishio; Manabu Shigeoka; Hiroshi Yokozaki
Journal:  Lab Invest       Date:  2020-05-26       Impact factor: 5.662

7.  Differential regulation of CD4+ T cell adhesion to cerebral microvascular endothelium by the β-chemokines CCL2 and CCL3.

Authors:  Kenneth Ky Liu; Katerina Dorovini-Zis
Journal:  Int J Mol Sci       Date:  2012-11-30       Impact factor: 5.923

8.  Analysis of Chemokine Receptor Trafficking by Site-Specific Biotinylation.

Authors:  Marcel Liebick; Christian Schläger; Martin Oppermann
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.